The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The lymphatic system extracts, transports and metabolizes lymph, the fluid found in between cells. The lymphatic system is similar to the circulatory system in terms of both its structure and its most basic function, to carry a body fluid.
3-Phosphoglyceric acid (3PG, 3-PGA, or PGA) is the conjugate acid of 3-phosphoglycerate or glycerate 3-phosphate (GP or G3P). This glycerate is a biochemically significant metabolic intermediate in both glycolysis and the Calvin-Benson cycle. The anion is often termed as PGA when referring to the Calvin-Benson cycle. In the Calvin-Benson cycle, 3-phosphoglycerate is typically the product of the spontaneous scission of an unstable 6-carbon intermediate formed upon CO2 fixation. Thus, two equivalents of 3-phosphoglycerate are produced for each molecule of CO2 that is fixed. In glycolysis, 3-phosphoglycerate is an intermediate following the dephosphorylation (reduction) of 1,3-bisphosphoglycerate.
I’ve always been a fan of much of the earliest electronic music. I’d say obviously from that era Brian Eno, Tangerine Dream, Synergy, Isao Tomita and Vangelis all influenced me. When I was growing up in New Zealand, I remember seeing a BBC clip of Emerson Lake and Palmer performing “Fanfare for the Common Man”. I just thought that huge analog synth looming over Emerson looked and sounded so cool -- I was hooked. I still find something totally unique about the sonic textures many of the early synth pioneers were able to create. At a time when a polyphonic synth setup could cost as much as several houses, I think it influenced the amount of time and thought invested in crafting unique sounds. On the defunct Half-Life website, his function was described as follows: "Kelly did all of the music and sound effects for Half-Life, and wrote sound code to create character speech and DSP reverb effects." On Valve's official website circa 1998, his function was described as follows: "Kelly, formerly a product unit manager at Microsoft, has a programming background that includes consumer multimedia, database engines, and networking. He created all the music and sound effects for Half-Life." As also stated on the website, he was the lead singer for the Seattle based band: Lucy's Fishing Trip In addition to composing the soundtrack for Half-Life 2, Bailey was one of four Valve employees – the others being David Speyrer, Eric Kirchmer, and Greg Coomer – who served as facial models for Gordon Freeman's face in the game's promotional materials.
Ethylene oxide is a surface disinfectant that is widely used in hospitals and the medical equipment industry to replace steam in the sterilization of heat-sensitive tools and equipment, such as disposable plastic syringes. It is so flammable and extremely explosive that it is used as a main component of thermobaric weapons; therefore, it is commonly handled and shipped as a refrigerated liquid to control its hazardous nature.
==== Anionic: sulfate, sulfonate, and phosphate, carboxylate derivatives ==== Anionic surfactants contain anionic functional groups at their head, such as sulfate, sulfonate, phosphate, and carboxylates. Prominent alkyl sulfates include ammonium lauryl sulfate, sodium lauryl sulfate (sodium dodecyl sulfate, SLS, or SDS), and the related alkyl-ether sulfates sodium laureth sulfate (sodium lauryl ether sulfate or SLES), and sodium myreth sulfate.
Sources: en.wikipedia.org
In coordination chemistry, EDTA4− is a member of the aminopolycarboxylic acid family of ligands. EDTA4− usually binds to a metal cation through its two amines and four carboxylates, i.e., it is a hexadentate ("six-toothed") chelating agent. Many of the resulting coordination compounds adopt octahedral geometry. Although of little consequence for its applications, these octahedral complexes are chiral. The cobalt(III) anion [Co(EDTA)]− has been resolved into enantiomers. Many complexes of EDTA4− adopt more complex structures due to either the formation of an additional bond to water, i.e. seven-coordinate complexes, or the displacement of one carboxylate arm by water. The iron(III) complex of EDTA is seven-coordinate. Early work on the development of EDTA was undertaken by Gerold Schwarzenbach in the 1940s. EDTA forms especially strong complexes with Mn(II), Cu(II), Fe(III), Pb(II) and Co(III). Several features of EDTA's complexes are relevant to its applications. First, because of its high denticity, this ligand has a high affinity for metal cations:
After founding Shapa, Ariely also co-founded the hedge fund Irrational Capital and its associated Clear Motivation Index. For the company, Ariely developed an index measuring human capital based on factors such as motivation and benefits, and created several ETFs based on human capital factor, including the funds listed as HAPI and HAPS.
The reduction of the permissible exposure limit (PEL) for respirable crystalline silica from 250 to 50 micrograms per cubic meter of air, averaged over an 8-hour shift. Shifts the focus of controlling silica exposure from the use of PPE (respirators) to the use of engineering controls (such as using water-integrated tools or vacuum systems) and administrative controls (limiting exposure time per shift). Employers are still required to provide respirators when engineering and administrative controls cannot adequately limit exposure. Additional provisions include limiting worker access to high exposure areas, signage requirements in high exposure areas, the development of a written exposure control plan, and training for workers on silica risks and how to limit exposures. Special equipment may be needed to prevent machine water from evaporating and leaving behind dust, and the standard also provides requirements for cleaning up the slurry left behind when water-integrated tools are used as an engineering control. Requires medical exams for highly exposed workers which include a discussion with a physician or licensed health care provider (PLHCP) of prior respiratory health, chest X-ray, pulmonary function test, latent tuberculosis infection, and any other tests deemed necessary by the PLHCP, which are to occur within 30 days of initial silica exposure and must be made available for renewal at least every three years unless the PLHCP deems otherwise.
A number of sweet carbonated beverages can be produced by the same methods as beer, except the fermentation is stopped sooner, producing carbon dioxide, but only trace amounts of alcohol, leaving a significant amount of residual sugar in the drink.
Sources: en.wikipedia.org
Day of Defeat was followed by Day of Defeat: Source, a remake of the game that runs on Valve's Source engine. The Source remake included significant changes to Day of Defeat's gameplay, new maps, updated graphics, and improved physics. Released on September 26, 2005 to favorable reviews, the game was praised for its gameplay, audio, and graphics. Post-release, the game was supported by Valve with a number of subsequent updates, including versions of the game for OS X and Linux released in 2010 and 2013 respectively.
== External links == Overview of all the structural information available in the PDB for UniProt: P09958 (Human Furin) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: P23188 (Mouse Furin) at the PDBe-KB.
(2026) present virtually reconstructed models of the face of the same individual. Choudhary et al. (2026) provided new paleomagnetic and stratigraphic data for the Ramnagar region of India, re-dating its primate-yielding localities to 13.03–11.59 Ma and extending the known chronological range of the primates like Sivapithecus, Kapi and Ramadapis by approximately 200,000 years. Evidence from the study of the cranial endocast of Rudapithecus hungaricus, indicative of presence of sulcal patterns similar to those seen in gorillas, is presented by Assance, Silcox & Begun (2026). Spassov et al. (2026) report the discovery of a nearly complete femur of cf. Graecopithecus from the Miocene strata from the Azmaka-6 locality near Chirpan (Bulgaria), sharing morphological traits with both quadrupeds and bipeds, and interpreted as indicative of a transitional locomotor repertoire including both terrestrial quadrupedalism and an early form of facultative bipedalism. Evidence from the study of teeth and the bony labyrinth of Oreopithecus bambolii, interpreted as indicating that the studied primate was more likely to be a derived stem hominoid than a close relative of Miocene apes from Europe or gibbons, is presented by Urciuoli et al. (2026). Jansma & Locke (2026) interpret Xenopithecus koruensis as a valid basal hominoid taxon distinct from Proconsul africanus. Williams et al.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.